Abstract
Background: Due to its poor prognosis and mortality rates, heart failure (HF) has been recognized as a malignant condition, comparable to some cancers in developed countries. Objectives: To compare mortality from HF and prevalent cancers using data from a nationwide database in Brazil. Methods: This was a descriptive, cross-sectional study using secondary data obtained from Brazilian administrative databases of death records and hospitalization claims maintained by the Ministry of Health. Data were analyzed according to main diagnosis, year of [...]
Highlights
More than 64 million people live with heart failure (HF) in the world.[1]
Due to its progressive nature, HF is characterized by high mortality in the advanced phase, and its prognosis varies widely according to the population studied.[1]
The international literature is abundant in articles addressing HF mortality, there are no data to support that HF mortality is higher than cancer mortality in Brazil
Summary
More than 64 million people live with heart failure (HF) in the world.[1]. Due to its progressive nature, HF is characterized by high mortality in the advanced phase, and its prognosis varies widely according to the population studied.[1]. Mamas et al.,[12] in a more recent review, showed that the statement presented by McMurray and Stewart remains valid until today, allowing us to conclude that HF is a more malignant disease than many types of cancer.[12]. Due to its poor prognosis and mortality rates, heart failure (HF) has been recognized as a malignant condition, comparable to some cancers in developed countries. Objectives: To compare mortality from HF and prevalent cancers using data from a nationwide database in Brazil. HF showed mortality rates of 100-150 per 100,000 inhabitants over the period, lower than the selected cancers. HF had a higher mortality rate than each type of cancer, even when compared to the most prevalent and deadly ones. HF was associated with a higher risk of hospitalization when compared to cancer-related conditions as a group.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
